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Abstract 
Craniosynostosis is a common craniofacial birth defect. It’s clinical presentation, (genetic) diagnosis and 
treatment is discussed in detail elsewhere in this special issue of Molecular Syndromology. This review 
focuses on the advances that have been achieved through studying the pathogenesis of craniosynostosis using 
mouse models. Classic methods of gene targeting which generate individual gene knockout models have 
successfully identified numerous genes required for normal development of the skull bones and suture. 
However, the study of syndromic craniosynostosis has largely benefited from the production of knockin 
models that precisely mimic human mutations. These have allowed the detailed investigation of downstream 
events at the cellular and molecular level following otherwise unpredictable gain of function effects. This has 
greatly enhanced our understanding of the pathogenesis of this disease and has the potential to translate into 
improvement of the clinical management of this condition in the future. 
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Introduction 
Craniosynostosis is a common feature of craniofacial birth defects, with a prevalence of 1:2,500 births (Cohen 
and Kreiborg, 1992). It is characterized by premature fusion of calvarial bones and can occur along single or 
multiple cranial sutures. Around 30% of craniosynostosis occurs within a characterised craniofacial syndrome 
(‘syndromic craniosynostosis’) with a genetic cause, whilst the majority of non-syndromic cases have a de 
novo cause (‘non syndromic craniosynostosis’) (Johnson and Wilkie, 2011). The molecular basis for 
craniosynostosis is complex: for example, a genetic cause such as a dominant mutation within one of the 
Fibroblast Growth Factor Receptor (FGFR) 1, 2 and 3 genes are well known, yet, environmental factors, most 
notably intra-uterine head constraint, has also been hypothesized as among the predisposing factors to this 
condition (Muenke et al., 1997, Muenke et al., 1994, Reardon et al., 1994, Johnson and Wilkie, 2011). The 
phenotypic consequence of craniosynostosis is skull shape distortion with secondary sensory-neurological 
deficits through an increase of intracranial pressure (Derderian and Seaward, 2012). Typically, FGFR 
mutations are responsible for the ‘Crouzonoid’ phenotype comprising of complex craniosynostosis, midfacial 
hypoplasia, strabismus and brachycephaly (Johnson and Wilkie, 2011). As a result of craniosynostosis, 
symptoms include optic atrophy, blindness and hearing deficits (Derderian and Seaward, 2012). There is 
currently no pharmacological treatment for craniosynostosis, with repeating surgical modalities the primary 
option to accommodate normal brain growth by correcting skull dysmorphology and reducing intracranial 
pressure, a procedure known as craniectomy (Johnson and Wilkie, 2011). Specifically, surgical interventions 
aim to re-open the suture (‘distraction osteogenesis’) with calvarial remodelling (Park and Yoon, 2012).  
Historically, a mutation in the MSX2 (Msh homeobox 2) gene was first to be associated with syndromic 
craniosynostosis, eliciting a clinical phenotype known as ‘Boston-type craniosynostosis’ (Jabs et al., 1993). 
Mutations in genes encoding FGFRs were identified later and are perhaps the most common genes involved in 
syndromic craniosynostosis (Wilkie, 2005). The most notable characteristics of craniofacial dysmorphology 
are often referred to as the ‘Crouzonoid’ phenotype, with coronal synostosis being the most common type of 
suture fusion (Wilkie and Morriss-Kay, 2001). This usually results from autosomal dominant mutations that 
constitutively activate the FGF receptor and as such can be thought of as ‘gain-of-function’ (GOF) mutations 
(Wilkie, 2005). A generalisation is that the craniofacial spectrum elicited by FGFRs signalling misregulation 
3 
 
will depend on the tissue specificity and precise allelic mutation within the receptor gene (Wilkie, 2005). 
Allelic mutations affecting the ligand binding domain (S252, P253, C278 and C342) account for 80% of all 
craniosynostosis cases. An interesting observation first mentioned by Wilkie (2005) is that identical 
substitutions across all FGFR paralogues are conserved at equivalent positions along the gene. For example, 
an amino acid change within the linker region of each receptor such as Proline 250 to Arginine (p.Pro250Arg), 
gives rise to either Pfeiffer (FGFR1), Apert (FGFR2) or Muenke (FGFR3) syndromes, with coronal synostosis 
being a common phenotype of all three (Wilkie, 2005). FGFR1, 2 and 3 are all expressed along the edges of 
the calvarial bones with FGFR2 predominant in the osteogenic front (Johnson et al., 2000, Iseki et al., 1999). 
However, the spatial localisation of the various splice forms is not well-characterised due to their high 
sequence homology. Instead, it is mainly through isoform specific knockouts in mouse models that their 
individual functions have been delineated (see below). 
Undeniably, mouse models have offered a significant platform to study human disease progression, and 
generating models carrying specific knockin mutations can help to address questions concerning the 
phenotypic diversity caused by the various mutations identified in patients. Whilst a large body of research 
has focussed on the genomic landscape, the biochemical and transcriptomic consequences that influence 
cellular activity in vivo still remains to be fully elucidated. In order to advance translation to clinical practice, 
it will be critical to address the aberrant mechanisms that lead toward these craniofacial abnormalities. In this 
review, we will provide an overview of the currently available mouse models that have been associated with 
various forms of syndromic craniosynostosis (Table 1). Finally, we will draw conclusions about the work 
done so far and make suggestions where future research into this area is headed.  
I FGF signalling related mouse models of human syndromic craniosynostosis 
Fibroblast Growth Factor Receptors (FGFRs) 
FGFR1 
Mutations in FGFR1 have been reported in Kallman, Jackson-Weiss, Muenke and Pfeiffer Syndromes (Ornitz 
and Itoh, 2015). In addition to the common craniofacial abnormalities, severe Pfeiffer syndrome patients 
exhibit limb and digit abnormalities (Muenke et al., 1994). Specifically, these patients have varying degrees of 
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syndactyly, finger truncation, broad digits and short limbs (Muenke et al., 1994). The GOF p.P252R 
substitution responsible for Pfeiffer syndrome was originally identified in the early 1990s, affecting exon 5 of 
FGFR1, common to both splice forms (Muenke et al., 1994). The mutation was eventually reproduced in the 
mouse genome, creating a model for Pfeiffer syndrome (Fgfr1P250R/+) with bi-coronal craniosynostosis along 
with enhanced expression of osteogenic genes (Zhou et al., 2000). Additionally, these mice have increased 
cell proliferation at postnatal day (P)5 in the sutures. On the other hand, loss of function (LOF) mutations (i.e. 
G237S, P722H and N724K) in this receptor are more usually associated with hormone dysregulation than 
with skeletal defects, and are related to Kallman syndrome (Pitteloud et al., 2006). Fgfr1 is expressed 
prominently in the distal limb bud between E8.5-E12.5, and is required for its correct initiation and outgrowth 
(Verheyden et al., 2005, Li et al., 2005). Conditional inactivation of Fgfr1-/- in the limb bud mesenchyme 
(TCre) do result in long bone and digital defects during later stages of development, similar to those in Pfeiffer 
patients (Verheyden et al., 2005, Li et al., 2005). Therefore, the differential phenotype elicited by LOF 
mutations in humans and knockout mice suggest dosage sensitivity of FGFR1 signalling.    
Complete abrogation of FGFR1 signalling is highly potent and embryonic lethality is consistently reported 
throughout the literature (Deng et al., 1994, Yamaguchi et al., 1994). Multiple strategies have been adopted to 
ameliorate this problem, including generation of hypomorphic models by reducing the expression of full 
length FGFR1, mutating binding sites for Frs2 on Fgfr1, or preventing Trk autophosphorylation (Partanen et 
al., 1998). Additionally, Partanen and colleagues (1998) have achieved isoform specific knockout to exons 8 
(IIIb) and 9 (IIIc) by inserting a stop codon into these exons. Fgfr1b appears to be the major player in axial 
skeleton development, as Fgfr1b-/- mice display vertebrate column truncations and limb abnormalities, despite 
the craniofacial skeleton remains largely normal. Thus, the lack of a craniofacial phenotype exhibited by 
FGFR1 LOF implies its role in craniofacial development is minor. However, the Fgfr1c knockout mouse is 
embryonic lethal suggesting the importance of the mesodermal isoform in early embryogenesis (Partanen et 
al., 1998).  
FGFR2 
FGFR2 is a positive regulator for osteoblast differentiation and manipulating this signalling pathway has 
consequences for osteoblastogenesis. It is well characterised that Runx2, the master regulator for osteoblast 
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differentiation, is downstream of FGFR2 signalling (Miraoui et al., 2009). Therefore, a substantial proportion 
of clinical syndromes and bone diseases have been related to signalling misregulation caused by this receptor. 
The role of FGFR2 was first characterised using knockout models. Several groups have generated Fgfr2 
knockout lines with similar phenotypes, yielding a series of gastrulation, placental and osteogenesis defects 
(Yu et al., 2003, Arman et al., 1998, Arman et al., 1999, Xu et al., 1998). The first FGFR2 knockout was 
generated by targeted disruption to the kinase domain of the receptor, preventing autophosphorylation (Arman 
et al., 1998). Other Fgfr2 knockouts followed, by disrupting immunoglobulin loops along the receptor gene 
(Xu et al., 1998). Xu et al., generated a knockout by removing exons encoding the IgIII loop responsible for 
ligand specificity. Despite homozygous lethality at E10.5, this study was the first to gain insights into the role 
of FGFR2 in limb development as these mutants fail to develop limb buds due to a loss of paracrine signalling 
that is responsible for tissue outgrowth (Xu et al., 1998). It was later discovered from the Fgfr2b-/- model that 
the IIIb isoform is critical for limb outgrowth, as these mice have a complete loss of the appendicular skeleton 
(De Moerlooze et al., 2000, Revest et al., 2001). Fgf10 is a likely binding partner for FGFR2b, as Fgf10-/- mice 
exhibit striking similarities to Fgfr2b-/- mice (Sekine et al., 1999, Min et al., 1998). On the other hand, Fgfr2c-/- 
mice illustrate that this isoform is required for normal craniofacial development as bi-coronal synostosis and 
under development of the auditory bulla were reported characteristics (Eswarakumar et al., 2002). Others have 
also generated conditional Fgfr2 knockouts to study tissue specific effects: Conditional knockout in the 
mesenchyme using Dermo1Cre leads to defects in both axial and craniofacial skeleton (Yu et al., 2003). 
Specifically, these mice have decreased bone density, truncated femurs owing to insufficient chondrocyte and 
osteoblast proliferation, brachycephaly and dwarfism (Yu et al., 2003).  
A large cohort of characterised craniofacial syndromes are commonly associated with FGFR2 germline 
mutations (Wilkie, 2005). GOF mutations in the FGFR2 gene are characteristic of Apert, Crouzon, and Beare-
Stevenson syndromes (Wilkie, 2005) and establish that FGFR2 signalling is a key player in craniofacial 
development. Crouzon syndrome is most commonly caused by a substitution mutation in FGFR2c (FGFR2c-
p.C342Y; at the DIII Ig loop) and is autosomal dominant (Reardon et al., 1994). The substitution of a cysteine 
to a tyrosine residue results in the stabilization of intermolecular disulphide bonds at the receptor extracellular 
domains, leading to constitutive activation (Eswarakumar et al., 2005). The phenotypes affecting the IIIc 
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isoform in Crouzon syndrome are mainly craniofacial, whilst the p.S252W mutation found in Apert syndrome 
is associated with additional limb phenotypes such as truncation and syndactyly, since the mutation affects 
both FGFR2 splice variants (Johnson and Wilkie, 2011). Mouse models are available for the most common 
FGFR2 craniofacial syndromes:  Fgfr2cC342Y/+ (Crouzon), Fgfr2cW290R/+ (Crouzon) and Fgfr2S250W/+ (Apert) 
(Wang et al., 2005, Eswarakumar et al., 2004, Mai et al., 2010, Chen et al., 2003). A common characteristic in 
these models are shortened midface, brachycephaly and coronal suture obliteration, which mimicks the human 
disease phenotype. Interestingly, none of these models, including Apert mice, display a limb phenotype. On a 
cellular level, these mutations affect FGFR2 function by altering osteoblast proliferation, differentiation and 
apoptosis in the suture. Eswaraskumar et al 2004 reported from around E13.5 an early increase in cellular 
activity at the osteogenic front that is responsible for suture obliteration in Fgfr2cC342Y/+ (Eswarakumar et al., 
2004). Chen et al., 2003, however, reported increased apoptosis as being a key player for coronal synostosis 
development in a separate mouse model for Apert syndrome (Fgfr2S250W/+) (Chen et al., 2003).  
It is not well understood how a separate allelic mutation, also affecting the transmembrane domain of FGFR2, 
gives rise to Beare-Stevenson syndrome (Fgfr2Y394C/+) (Wang et al., 2012). Similar to the C342Y mutation, 
FGFR2-Y394C stabilises intermolecular bonds of unpaired cysteine residues leading towards constitutive 
activation. However, despite showing craniofacial similarities, Beare-Stevenson patients have additional skin 
abnormalities including cutis gyrate (thickened scalp) and acanthosis nigricans (hyper pigmentation) (Wang et 
al., 2012). A mouse model has been generated to study this mutation (Fgfr2Y394C/+), but the pathogenic origin 
of the cutaneous phenotype still remains unclear (Wang et al., 2012). In addition to introducing GOF 
mutations, increasing gene dosage also allows the identification of novel phenotypes in animal models. For 
example, a detailed analysis of Fgfr2cC342Y/C342Y homoygotes identified exencephaly, overt cleft of the 
secondary palate and a series of segmentation defects along the axial skeleton (Peskett et al., 2017). 
Due to a common craniofacial phenotype elicited in animal models for syndromic synostosis, they provide a 
robust platform to test novel therapeutic approaches and evaluate the safety of potential clinical treatments. 
For instance, Shukla et al., 2007 attempted to rescue the coronal suture in Fgfr2S252W/+ mice through 
knockdown of the RAS-MAPK pathway with short-hairpin RNA (shRNA) or MEK-ERK inhibition using 
U0126 treatment. Despite some rescue of the suture, longitudinal evaluation of these mice revealed growth 
7 
 
restriction in a proportion of treated animals along with spontaneous unexplained death in others (Shukla et 
al., 2007). Indeed, the activating nature of FGFR2 has led to the assumption that attenuation of downstream 
signalling is sufficient to rescue craniofacial malformations (Shukla et al., 2007, Pfaff et al., 2016). Several 
studies were able to demonstrate this in vivo: Firstly, craniofacial morphology was rescued when a mutant 
Frs2α allele was introduced onto the Fgfr2cC342Y/+ mouse, which prevented activation of the downstream 
RAS-MAPK pathway (Eswarakumar et al., 2006). Secondly, systematic MAPK knockdown using shRNA or 
U0126 treatment was also sufficient to rescue craniosynostosis in Fgfr2S252W/+ (Shukla et al., 2007). However, 
the idea of simply dampening the signal as a potential therapy may well be over-simplistic given the 
complexity of pathogenic FGFR2 signalling. Snyder-Warwick et al 2010 examined the nature of FGF 
signalling output in the palates of the Crouzon mouse model (Snyder-Warwick et al., 2010). The authors 
found that Spry2, Spry4, Etv5 and Dusp6, all direct targets of FGF signalling, were downregulated at multiple 
developmental stages (Snyder-Warwick et al., 2010). At the cellular level, these embryos had reduced cellular 
proliferation that resulted in a delay to palatal shelf elevation. Moreover, isoform specific knockout of Fgfr2c 
(Fgfr2c-/-) was sufficient to phenocopy the effects of Fgfr2cC342Y/+ with apparent coronal synostosis 
(Eswarakumar et al., 2002). The paradoxical nature of FGFR2c signalling remains to be elucidated, but it is 
generally accepted that an intricate balance of signalling activity is required for normal development. 
FGFR3 
FGFR3 is a negative regulator for bone formation (Deng et al., 1996). A number of FGFR3 knockout lines 
using different targeting methodologies have been reported, all showing consistent bone overgrowth 
phenotypes (Deng et al., 1996, Colvin et al., 1996, Eswarakumar and Schlessinger, 2007). The most notable 
characteristic is that these mice are larger in size as a consequence of ectopic chondrogenesis (Deng et al., 
1996, Colvin et al., 1996). Despite this, their bones have increased porosity, most likely due to a reduction in 
bone mineralisation. Analysis of isoform specific knockouts revealed that the Fgfr3c isoform is responsible 
for the hyperplastic phenotype (Eswarakumar and Schlessinger, 2007). In turn, an actived FGFR3 pathway 
through GOF mutations in FGFR3 leads to increased negative regulation of endochondral bone formation and 
is associated with short-limbed dwarfism caused by skeletal dysplasias such as achondroplasia and 
thanatophoric dysplasia (Rousseau et al., 1994, Shiang et al., 1994, Bellus et al., 1995). The first missense 
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mutation for achondroplasia was identified as a glycine 380 to arginine substitution (FGFR3-p.G380R) within 
the transmembrane domain of FGFR3 (Shiang et al., 1994, Bellus et al., 1995). This mutation decreases 
receptor trafficking from the membrane, resulting in increased levels of phosphorylation during exposures to 
FGF ligands and signalling activation (Monsonego-Ornan et al., 2000). Histological analysis reveals a 
saturation of FGFR3 at mutant mouse growth plates, coincided with fewer chondrocytes in growth plates and 
hypertrophic zones (Monsonego-Ornan et al., 2000, Segev et al., 2000). Several mouse models have been 
made for achondroplasia such as Fgfr3G374R/+ and Fgfr3G369C/+, which also affect the transmembrane domain 
(Wang et al., 1999, Chen et al., 1999). Other models integrated a transgene containing the human FGFR3-
p.G380R cDNA into the mouse genome, phenocopying the human disease (Segev et al., 2000, Lee et al., 
2017). In addition to the dwarfism phenotype, these mice also display brachycephaly and brain distortion 
(Wang et al., 1999). Thanatophoric dysplasia is the most severe form of dwarfism (Tavormina et al., 1995). 
The genetic differences that separates acondroplasia and thanatophoric dysplasia can be explained by different 
modes of receptor activation. Mutations that result in achondroplasia are caused by ligand dependent receptor 
over-activation, whilst mutant FGFR3 for thanatophoric dysplasia are constitutively active (Ornitz and Itoh, 
2015). Mutations responsible for thanatophoric dysplasia stabilises intramolecular bonds of FGFR3 at either 
the transmembrane domain (Fgfr3S365C/+) or the ligand specific domain (Fgfr3Y367C/+) (Chen et al., 2001, 
Pannier et al., 2009, Ornitz and Itoh, 2015). In humans, a further mutation affecting the TRK domain e.g. 
FGFR3-p.K650E was identified, but a mouse model is not yet available, perhaps owing to the potency of 
mutations affecting the kinase domain (Ornitz and Itoh, 2015). There have been reports linking 
craniosynostosis to achondroplasia and thanatophoric dysplasia in the literature but these links are not yet well 
established. For example, some patients with thanatophoric dysplasia exhibit a cloverleaf skull, suggestive of 
severe craniosynostosis (Tavormina et al., 1995), another mutation for achondroplasia-FGFR3-p.A391E, has 
been identified in Beare-Stevenson patients (Meyers et al., 1995) and similarly in the mouse, whilst an 
isolated study reports coronal synostosis in Fgfr3G380R/+ (Lee et al., 2017).  
The p.P250R mutation is the most common mutation identified in all three FGFR paralogues (Wilkie, 2005). 
In FGFR3, this leads to Muenke syndrome, where unilateral or bicoronal synostosis is an apparent 
characteristic (Muenke et al., 1994). The p.P250R mutation affects both FGFR3 isoforms, and results in 
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increased affinity for FGF ligands (Muenke et al., 1994, Wu et al., 2009). A knockin of this mutation in the 
mouse recapitulated Muenke syndrome (Fgfr3P244R/+) (Twigg et al., 2009). However, the craniofacial 
phenotype was incompletely penetrant due to background differences between mouse strains. Despite the 
variability observed in the general craniofacial skeleton, it has been a useful mouse model for studying inner 
ear development (Mansour et al., 2009, Mansour et al., 2013). Muenke individuals were reported to have poor 
sensory reception towards the low end of the auditory spectrum (Mansour et al., 2009). Analysis of the 
Fgfr3P244R/+ mouse identified multiple disruptions to the cochlear duct cytoarchitecture with alterations to the 
overall balance of support cells, with bias towards Dieter cell fate differentiation (Mansour et al., 2013, 
Mansour et al., 2009). This change of fate was largely due to the mutation causing the receptor losing ligand 
specificity, allowing ligands to bind promiscuously to both Fgfr3b and Fgfr3c isoforms (Mansour et al., 
2013). Genetic rescue of the ear phenotype can be achieved by reducing expression of Fgf10, a ligand specific 
to both the FGFR3b isoform, in compound mutants (Fgfr3P244R/+; Fgf10+/-) (Mansour et al., 2013). Perhaps this 
study offers a useful insight into the reason why craniosynostosis does not develop in the Muenke mouse 
model, since in addition to background strain, available ligands in the coronal suture can act as limiting factors 
to the proposed phenotype.  
FGF ligands 
The embryonic coronal suture express a repertoire of FGF ligands (Hajihosseini and Heath, 2002). However, 
it is not known how FGF ligands coordinate craniofacial development or regulate suture patency. The 
question is complex largely due to FGF ligands having multiple affinities toward different FGF receptors 
(Zhang et al., 2006). Therefore, abrogation of FGF genes in vivo is likely to result in a redundant phenotype 
(Zhang et al., 2006, Barak et al., 2012, Wright and Mansour, 2003). In light of this, determining whether a 
phenotype is a consequence of a single FGF ligand or a combination working synergistically remains a 
challenge. FGF ligands are abundant during development and any genetic perturbation will most likely result 
in defects to organogenesis. One of the main purposes of FGF signalling in development is to mediate cross 
talks between the mesenchyme and epithelium (Ornitz and Itoh, 2015). The most common FGF ligands 
involved in this process include epithelially expressed FGF9 and FGF10 in the mesenchyme, each signalling 
reciprocally to their tissue specific FGFR isoforms (Ornitz and Itoh, 2015). An example of tissue specific 
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interaction can be seen  in the developing limb bud, which institutes a positive feedback loop regulating its 
outgrowth (Li et al., 2007, Revest et al., 2001). Thus, genetically disrupting the tight coordination results in a 
series of skeletal dysplasias in the axial skeleton, largely affecting bone mass, densities and stunted growth 
(De Moerlooze et al., 2000, Revest et al., 2001, Eswarakumar et al., 2002, Eswarakumar et al., 2004). In 
addition to genetic approaches, surgical bead implantations soaked in different FGF ligands have been 
fundamental to understanding osteogenesis in vivo (Iseki et al., 1999). Explicitly, this classical embryology 
approach is well characterised to investigate the impact of specific ligands on the calvaria e.g. FGF2, to 
investigate ectopic osteogenesis (Iseki et al., 1999). All the FGF ligands are expressed in the coronal suture 
with the exception of FGF3 and FGF4 (Hajihosseini and Heath, 2002). To date there has not been a report of 
syndromic craniosynostosis associated with ligand function other than FGF9, although mutations in FGF3, 
FGF8 and FGF10 are sufficient to disrupt craniofacial development (Ornitz and Itoh, 2015).  
Multiple synostoses syndrome 3 (SYNS3) is characterised by multiple fusion of synovial joints in the axial 
skeleton (Wu et al., 2009). It is autosomal dominant and is caused by a missense mutation in FGF9 (FGF9-
p.S99N) (Wu et al., 2009). A phenotype closely resembling MSS in the mouse, with fusions of the elbow and 
knee, has been reported in the Fgf9N143T/+ mouse (Harada et al., 2009). In addition to elbow-knee synostoses 
(EKS), these mice exhibit coronal synostosis. The consequence of the mutation has led to a loss-of-function 
for FGF9-heparin binding, which affects overall FGFR signalling potency. This protein interaction 
impairment resulted in hyper-diffusibility of the ligand in the extracellular matrix, encroaching into the joint 
and suture mesenchyme to induce synostosis. Additionally, mouse mutants carrying the missense mutation 
have ectopic expression of multiple osteoblast precursor markers such as Runx2 and Osteopontin in the 
coronal suture mesenchyme at E16.5 (Harada et al., 2009). FGF9 has high affinity towards the IIIc isoforms, 
in particular to FGFR3c (Zhang et al., 2006). Thus, coronal synostosis for Muenke syndrome is indirectly 
linked to FGF9, as the FGFR3-p.P250R mutation causing Muenke syndrome affects the affinity of FGFR3c to 
FGF9 (Harada et al., 2009, Muenke et al., 1997).  
Due to the promiscuity of ligand-receptor interaction, it is possible that ectopic expression of FGF ligands can 
also drive tissue specific phenotypes provided the receptors are expressed in the right tissue. In this scenario, 
Carlton and colleagues successfully phenocopied the Crouzon mouse model (Fgfr2cC342Y/+) by disrupting the 
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intergenic regions of Fgf3 and Fgf4, normally absent from the wild-type (WT) suture, with midfacial 
hypoplasia, brachycephaly and bi-coronal synostosis (Carlton et al., 1998). Phenotypic redundancy is a 
consequence of ligand compensation. For example, in respect to FGF9, a fully penetrant urogenital tract 
defect is only observed when both Fgf9 and Fgf20 are knocked out (Barak et al., 2012). This is similar during 
cardiovascular morphogenesis, with partial penetrance when single deletions to Fgf3 and Fgf10 occurred 
together (Urness et al., 2011).  
In summary, the relatively small number of syndromic craniosynostosis cases associated with mutations in 
FGF ligands is likely due to ligand redundancies, especially given that the coronal suture expresses 20 of the 
22 FGF ligands (Hajihosseini and Heath, 2002). The spatial-temporal dynamics of FGF signalling, along with 
the diversity of FGF ligands functioning synergistically, makes biological data difficult to interpret. As 
biological signals are conveyed through the receptors, targeting FGFRs appear to yield more substantial 
phenotypes to that observed in ligands while giving direct interpretation to its function. 
II Other mouse models of human syndromic craniosynostosis 
Twist1 
The Twist gene family encodes two basic-helix-loop-helix transcription factors: Twist1 and Twist2 (also 
known as Dermo1) (Qin et al., 2012). Originally, Twist1 was demonstrated to be required for neural tube 
morphogenesis while Twist2, involved in regulating cytokine gene expression (Chen and Behringer, 1995, 
Sosic et al., 2003). Twist1 plays a variety of roles in mesoderm development focussing mainly in 
mesenchymal tissue and is expressed in the cranial mesenchyme (Bildsoe et al., 2013). Twist1 is expressed 
prominently in the suture mesenchyme and its inactivation in mice results in coronal synostosis (Behr et al., 
2011, Carver et al., 2002). This is due to Twist1 acting as a negative regulator of bone formation where it 
prevents osteoblast differentiation through Runx2 inhibition (Bialek et al., 2004). Runx2 deficient mice display 
delayed osteogenic activity in vivo, but introducing a copy of the Twist1 null allele into Runx2+/- (Runx2+/-; 
Twist1+/-) was sufficient to rescue a hypoplastic phenotype (Bialek et al., 2004, Komori et al., 1997). 
Conversely, in vitro analysis of Twist1 knockdown revealed decreased Runx2 expression with increased 
apoptosis (Yousfi et al., 2001, Maestro et al., 1999). Additionally, mutant Twist1 drives increased expression 
of FGFR2 in vitro and in vivo, perhaps as a compensatory effect, to upregulate the sensitivity of FGF 
12 
 
signalling for cellular survival (Miraoui et al., 2010, Connerney et al., 2008). With regard to disease 
pathogenesis, autosomal inheritance of LOF mutations in TWIST1 result in Saethre-Chotzen syndrome 
(Howard et al., 1997, el Ghouzzi et al., 1997). Saethre-Chotzen patients display complex suture abolishment 
most notably coronal, posterior frontal and lambdoid sutures with digit duplication (el Ghouzzi et al., 1997, 
Howard et al., 1997). The first Twist1 mouse mutant constructed by substituting exon 1 with a neo-cassette 
was described in 1995 in a study of cranial neural tube closure (Chen and Behringer, 1995). However, these 
Twist1 homozygotes were embryonic lethal by E11.5. Twist1+/- mice were viable with partial penetrance of 
limb and craniofacial phenotypes that replicated human disease according to the to genetic background of the 
animals (Bourgeois et al., 1998). In addition to Twist1 being a negative regulator for osteogenesis, it also 
functions to inhibit chondrocyte differentiation. Twist1+/- demonstrates enhanced chondrocytic activity in the 
coronal suture mesenchyme with upregulation of chondrocyte markers such as Sox9, Collagen II and Collagen 
X, but its significance is currently elusive (Behr et al., 2011). Contact inhibition may also play an important 
role in mediating Saethre-Chotzen syndrome, as both the Notch ligand Jagged1 (Jag1) and the ephrin 
receptor-EphA4 are downstream of Twist1. Conditional knockout of either Jag1 or EphA4 on a Twist1+/- 
background augments the craniosynostosis phenotype, whilst removal of either Jag1 or EphA4 is not 
sufficient to drive this pathogenesis (Ting et al., 2009, Yen et al., 2010). Both of these studies stress the 
importance of contact inhibition in controlling osteoblast differentiation in the mesenchyme, since conditional 
removal leads to mis-specification, and loss of positional information in specifying the suture boundary. 
Additionally, LOF mutations in JAG1 in humans are associated with Alagille syndrome, linking the 
pathogenesis of this syndrome to Saethre-Chotzen syndrome (Yen et al., 2010). bHLH proteins undergo a 
plethora of roles during development and tend to function as either hetero- or homo-dimers. bHLH proteins 
are classified by its tissue distribution, ability to dimerize and DNA binding specificities. Class I bHLH 
proteins are known as ‘E proteins’ and are abundant in multiple tissue types, whilst Class II e.g. Twist, have 
more restricted expression domains. Both Class I and Class II HLH proteins contain the basic domain and are 
DNA binding. Conversely, Class III proteins, which include Id, facilitate dimerization with E proteins and 
perturb formation of heterodimers between ClassI/II proteins (Massari and Murre, 2000). The degree of 
Twist1 syndromic craniosynostosis is related to their binding partners and the dimers they form. For example, 
a severe craniosynostosis phenotype is caused by a frameshift in Tcf12 in a Twist1 background (EIIaCRE/+; 
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Tcf12flox/-; Twist1+/+) (Sharma et al., 2013). Tcf12 is an E protein, and the inability to form the Twist1-Tcf12 
heterodimer results in a severe phenotype. The same scenario occurs to LOF of bHLH inhibitors Id1 and Id3 
under a Twist1 heterozygous background, with the former showing greater penetrance (Id1+/-; Twist1+/-) 
(Connerney et al., 2008).        
Msx2 
Mutations in MSX2 are associated with Boston type craniosynostosis (Jabs et al., 1993). Substitution of a 
histidine 148 to a proline (p.His148Pro) increases the binding affinity of MSX2 to its target DNA sequence 
(Ma et al., 1996). Msx2 is expressed in the sagittal and lambdoid sutures of the mouse, and its overexpression, 
which can be either of a WT allele or through a GOF mutation (Msx2P7H/+), leads to narrowing of the sagittal 
suture and abnormal bone overgrowth, particularly to the parietal bone (Liu et al., 1995). In contrast, MSX2 
haploinsufficiency in humans leads to ectopic calvarial foramen and delayed suture closure, due to the loss of 
binding affinity to target DNA (Wilkie et al., 2000). A similar observation is reported upon knockout of Msx1 
and Msx2 in vivo (Roybal et al., 2010).  The ectopic foramen was not a consequence of an embryonic 
patterning defect but rather, a mitotic decrease in the bone, likely from the ossification centre (Roybal et al., 
2010, Ishii et al., 2003). Msx2 and Twist1 interact to coordinate cellular proliferation and differentiation: 
Firstly, haploinsufficiency of both genes lead to ectopic frontal foramen formation and secondly, knockout of 
both alleles result in increased phenotypic severity (Ishii et al., 2003). Analysis of embryos between E12.5 and 
E14.5 revealed that the pathogenesis is mainly a reduction of osteoblast differentiation beginning at E12.5. It 
is interesting to note that the transcripts of these genes do not display the same expression pattern 
embryonically, but do lead to the same phenotypic outcome. Therefore, this suggests these transcription 
factors may work synergistically as a co-factor to derive the same phenotype at the protein level (Ishii et al., 
2003).  
Hedgehog related genes 
Gli3 LOF is associated with Greig cephalopolysyndactyly (GCP). GCP is an autosomal dominant disorder 
affecting both limb and craniofacial development (Hui and Joyner, 1993). The most notable characteristic 
includes supernumeric fingers (polydactyly), macrocephaly and a broad forehead with an additional 
phenotype being lambdoid synostosis (Rice et al., 2010). Gli3 is primarily a repressor of Hedgehog signalling, 
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which its LOF exacerbates, resulting in GCP. Specifically, GCP is caused by deletions to 7p13 on the human 
chromosome, and is also mapped to the same region in the mouse genome (Hui and Joyner, 1993). Johnson 
(1967) developed the first mouse model ‘Xtra Toes’, Gli3Xt-J/Xt-J (Xt-J), carrying an intragenic deletion of Gli3 
(Johnson, 1967, Hui and Joyner, 1993). Augmented Hedgehog signalling is related to Carpenter syndrome, 
through LOF to RAB23 (Ras-related protein Rab23)- a separate negative regulator of Hedgehog signalling 
preventing signalling transduction through Gli2 repression (Jenkins et al., 2007, Eggenschwiler et al., 2006). 
Carpenter syndrome patients display pan synostosis, but Rab23-/- mice do not recapitulates its phenotype and 
is embryonically lethal (Eggenschwiler et al., 2001). Thus, the Gli3Xt-J/Xt-J was used to study Hedgehog 
misregulation in craniosynostosis instead (Rice et al., 2010). Further analysis of Gli3Xt-J/Xt-J reveals ectopic 
osteoblast differentiation in the lambdoid sutures, which leads to early suture abolishment. Lambdoid 
synostosis can be rescued through augmentation of FGF signalling, which upregulates expression of Twist1 
(Rice et al., 2010, Rice et al., 2000). Interestingly, missense mutations to human MEGF8 (multiple EGF like 
domain 8) phenocopies features observed in Carpenter Syndrome (Twigg et al., 2012). Additionally left-right 
asymmetry and cardiac defects, were also reported in a mouse mutant (Megf8C193R/+) generated as a result of a 
large-scale mutagenesis screen (Zhang et al., 2009, Aune et al., 2008). However, craniofacial or skeletal 
defects were not analysed in this paper. It is unclear as to the role of Megf8 during development, but the close 
resemblance between MEGF8 and Carpenter syndrome suggests the mechanism responsible is highly similar. 
One might speculate effects on early development, and given by the abnormalities in left right-asymmetry, it 
is likely to affect both Nodal and Hedgehog signalling. This is supported by the recently demonstration that 
Megf8 dampens Hedgehog signalling in the primary cilia and that could explain the phenotypic similarities to 
Carpenter syndrome caused by RAB23 mutation (Pusapati et al., 2018).  
Masp1 and Colec11 
MASP1 (Mannose associated serine protease 1), Colec10 and Colec11 (Collectin subfamily 10 and 11) are 
components of the lectin pathway that is associated with inflammation. Mutations in these genes contribute to 
the pathogenesis of 3MC syndrome (Rooryck et al., 2011, Urquhart et al., 2016, Munye et al., 2017) which is 
the collective term for multiple related syndromes (Carnevale, Mingarelli, Malpuech and Michels syndromes) 
(Titomanlio et al., 2005). Common clinical features include craniosynostosis, cleft palate, hypertelorism, 
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hearing deficits, growth deficiencies and heart defects (Titomanlio et al., 2005), which are consequently 
suggested to be affected during development by abrogation to cytokine signalling (Newton and Dixit, 2012). 
Multiple amino acid changes in MASP1 and COLEC11 have been identified in human patients, predominantly 
resulting in a frameshift and LOF of the mature protein (Rooryck et al., 2011). There is no mouse model that 
describes 3MC at present. However, a double knockout of Masp1 and Masp3 (Masp1/3+/-) is reported in the 
literature without describing any obvious role in craniofacial development (Takahashi et al., 2008).  
Hdac4 
Histone deacetylases (HDAC) modulate gene expression by altering chromatin structure and repressing 
transcription factors. Brachydactylyl mental retardation syndrome (BMRS) occurs as a consequence of the 
LOF of HDAC4 (Williams et al., 2010), commonly due to deletion of Chr2q37 region that includes the 
HDAC4 gene. Clinical presentation of BMRS includes craniofacial dysmorphology with craniosynostosis, 
developmental delay, obesity and mental deficit on the autistic spectrum (Williams et al., 2010). HDAC4 can 
bind to the Runx2 promoter and as such is a regulator of the rate of ossification (Vega et al., 2004). Hdac4-/- 
mice show premature ossification of endochondral structures, whilst overexpression of Hdac4 in the 
chondrocytic lineage (Col2a1-Hdac4) results in cartilage dysplasia (Vega et al., 2004). However, the authors 
did not report any craniofacial abnormalities in the Hdac4 knockouts. The contribution of the role of 
(endochondral) cartilage in the process of suture abolishment remains elusive, despite a recent study showing 
that ectopic chondrocytes invading the suture mesenchyme lead to endochrondral ossification in a PDGFR 
mutant (He and Soriano, 2017). 
TGF signalling misregulation 
TGFβ signalling misregulation is associated with Marfan syndrome, a rare disorder occurring in 
approximately 1: 5,000 individuals (Judge and Dietz, 2005). Marfan syndrome is a complex disease affecting 
multiple systems, including craniofacial and skeletal dysmorphology, cardiovascular abnormalities, tissue 
fibrosis, ocular, and mental deficits (Judge and Dietz, 2005). Loeys-Dietz disease and Shprintzen-Goldberg 
syndrome, have a varying phenotypic spectrum of the described ‘Marfanoid phenotype’ (MacCarrick et al., 
2014, Carmignac et al., 2012, Loeys et al., 2005, Judge and Dietz, 2005). In particular, patients with 
Marfanoid phenotype and craniosynostosis are commonly referred to as ‘Shprintzen-Goldberg syndrome’. 
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Missense mutations in the extracellular matrix protein Fibrillin 1 (FBN1) was first identified to be associated 
with Marfan syndrome, and has been implicated in craniosynostosis (Dietz et al., 1991, Sood et al., 1996). 
However, multiple knockin models have been described in the mouse without recapitulating craniosynostosis 
(Carta et al., 2006, Judge et al., 2004, Ng et al., 2004, Pereira et al., 1999). Mutations causing LOF of the TGF 
signalling repressor, SKI, are associated with Shprintzen-Goldberg syndrome indicating a potential role for 
this signalling pathway in craniosynostosis (Doyle et al., 2012, Carmignac et al., 2012). Mutations in TGFBR1 
and TGFBR2 were identified as the cause of Loeys-Dietz disease (Loeys et al., 2005), a condition that 
typically presents with cardio-ventricular and outflow tract abnormalities, cleft palate, hypertelorism and 
occasionally craniosynostosis (Loeys et al., 2005). Substitution mutations in TGFBR1 and TGFBR2 augment 
TGF signalling activity, as shown by an increase of the pSMAD readout, and are therefore considered as GOF 
mutations (Loeys et al., 2005). Craniosynostosis of varying severity has been reported in mice with mutations 
in both of these receptors (Tgfbr1M318R/+ and Tgfbr2G357W/+) (Gallo et al., 2014). In particular, Tgfbr1M318R/+ has 
partial coronal synostosis with additional kyphosis in the thoracic region (Gallo et al., 2014).  
III Mouse models indirectly associated with human syndromic craniosynostosis   
The previous sections described mouse mutants that model human mutations causing syndromic 
craniosynostosis. In addition, there are numerous mouse mutants that are not based on human genetic 
mutations (i.e. knockin mutants) that also exhibit craniosynostosis. A substantial number of these mutants are 
related to growth factor signalling misregulation. Further to Fgfr2C342Y/+, isoform specific knockouts such as 
Fgfr2b-/- and Fgfr2c-/- also display a craniosynostosis phenotype (Eswarakumar et al., 2002, De Moerlooze et 
al., 2000). In particular, Fgfr2c-/- mice  show coronal synostosis that phenocopies the Fgfr2cC342Y/+ mutant 
(Eswarakumar et al., 2002). The main difference between both models lies within the disease progression, 
where the latter shows an accelerated phenotype during early embryogenesis (Eswarakumar et al., 2002, 
Eswarakumar et al., 2004). Fgfr2b-/- displays a subtle form of craniosynostosis, with fusion of the parietal and 
squamous temporal bones (De Moerlooze et al., 2000). It is well established that a hallmark of craniosyostosis 
is the upregulation of the MAPK/ERK pathway. Indeed, knockout of (Dusp6-/-) a negative regulator of ERK, 
results in coronal synostosis (Li et al., 2007). Similarly, LOF mutations of the Ets2 repressor factor (ERF) are 
also implicated in compound craniosynostosis to the coronal and sagittal sutures (Twigg et al., 2013). ERF is 
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responsible for the export of active ERK from the nucleus in order to attenuate its transcriptional activation 
activities, and conditional knockout of ERF (ERFflox/-) recapitulates the phenotype observed in patients with 
LOF mutations (Twigg et al., 2013).  
Although not commonly associated with human craniosynostosis, Platelet derived growth factor (PDGF) 
signalling has also been related to craniofacial malformations and coronal synostosis (He and Soriano, 2017, 
Moenning et al., 2009, Soriano, 1997). This is most likely due to the conserved nature of growth factor 
signalling downstream of the receptor. Signalling misregulation in an isoform of the platelet derived growth 
factor receptor PDGFRα, is implicated in midline defects and a split face (Pdgfrα-/-) (Soriano, 1997). 
Moreover, οver-activation of PDGFRα (PdgfrαD842V/+) drives ectopic chondrogenesis, eliciting coronal and 
lambdoid synostosis through the P13K-AKT cascade (He and Soriano, 2017). A similar phenotype is 
replicated in a transgenic overexpression model located at the Rosa26 locus (R26RPdgfrα-D842V/+) (Moenning et 
al., 2009).  
In addition to growth factors, Wnt/β-catenin signalling is also a key player in regulating osteoblast 
proliferation and differentiation (Yu et al., 2005). In the absence of signalling activation, β-catenin is 
prevented from being translocated to the nucleus through degradation. Therefore, Wnt signalling modulators 
are critical to modulate signalling sensitivity. Axin serves as a scaffold for formation of a β-catenin 
degradation complex, and its degradation is therefore Axin dependent (Logan and Nusse, 2004). 
Augmentation of Wnt signalling by Axin2-/- results in coronal and interfrontal synostosis (Yu et al., 2005). 
Similarly, overexpression of Nel-like type 1 molecule (NELL1) elicits posterior frontal suture 
craniosynostosis, along with the partial closure of sagittal and coronal sutures (Zhang et al., 2002). NELL1 
was originally isolated from samples obtained from unilateral (non-syndromic) coronal synostosis patients, 
and is expressed in the mesenchyme and osteogenic fronts (Ting et al., 1999). NELL1 expression is 
upregulated in sutures undergoing premature fusion, and is believed to augment Wnt/ β-catenin signalling, 
through interactions with β-integrins in osteoblasts (Ting et al., 1999, James et al., 2015).  
There are a number of other craniosynostosis mutants reported in the literature. Growth differentiation factor 6 
(Gdf6) is a secreted morphogen associated with the BMP signalling pathway (Ducy and Karsenty, 2000). 
Mutants lacking both alleles of Gdf6 (Gdf6-/-) display coronal synostosis and appendicular skeleton 
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abnormalities, with fusion of the tarsals and carpals (Settle et al., 2003). Runx2 is indispensable for osteoblast 
differentiation, and overexpression of Runx2 in the mesenchyme, driven under the endogenous promoter Prx1 
(Prx1-Runx2), elicits multiple synostosis, inclusive of multiple joint fusions in the appendicular skeleton 
(Maeno et al., 2011). Metopic suture synostosis is caused by LOF mutations to Fras1 related extracellular 
related gene 1 (FREM1), and is a cause of trigonocephaly in humans (Vissers et al., 2011). Frem1 encodes a 
protein secreted by mesenchymal cells that aids extracellular matrix remodelling remodelling (Smyth et al., 
2004). In the mouse, Frem1 is expressed along the periphery of the frontal bone, immediately adjacent to the 
interfrontal suture (metopic eqivalent) (Vissers et al., 2011). The orginal mouse model ENU by mutagenesis 
Frem1Bat/+ is a hypomorph caused by exon skipping (Smyth et al., 2004) and an exon 2 knockout mouse is also 
available, Frem1qbrick/+ (Kiyozumi et al., 2006, Vissers et al., 2011). Both models harbour interfrontal 
synostosis, with the latter mutant possessing a stronger phenotype (Vissers et al., 2011). 
Conclusion/Future directions  
Mouse models have been central to the study of human disease. Together with lineage tracing reporters, the 
phenotypes caused by knock in mutations have been critical to understand the pathways required for 
craniofacial development. Furthermore, mouse models provide a platform to test novel therapeutic strategies 
and management techniques (Wang et al., 2015, Perlyn et al., 2006, Maruyama et al., 2016). However, it is 
well understood in the murine research community that mouse models of human disease sometimes exhibit 
differences in phenotypic end points, which might simply be due to species differences. These can be the 
result of differing genetic redundancies and sensitivities. An example of this can be seen for a RAB23 
mutation responsible for human Carpenter syndrome (Eggenschwiler et al., 2001, Jenkins et al., 2007). LOF 
of the mammalian homologue of RAB23 in the mouse results in exencephaly and early embryonic lethality 
implicating dosage dependency of the phenotype (Eggenschwiler et al., 2001). Other examples include Ets 
domain-containing transcription factor (ERF), where craniosynostosis is only observed in a mouse model 
harbouring a conditional allele (ErfΔ/-) reducing the expression level to about 30% in contrast to that of a 
heterozygote null allele (Erfdl1/-) where the reduction would be 50% (Twigg et al., 2013, Papadaki et al., 
2007). Similar can be said of those mouse models related to Marfan syndrome that do not recapitulate a 
craniofacial phenotype (Gallo et al., 2014, Judge et al., 2004, Ng et al., 2004, Pereira et al., 1999).  
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The ability to generate gene knockout models has been pivotal in our understanding of gene function, and this 
in turn is dependent upon successful and accurate targeting of the specific allele of interest. Therefore, it 
makes sense that the overall design of a targeting vector is vital to reproducibly of a consistent phenotype. 
However, there are instances in the literature where a wide phenotypic spectrum can be produced. Examples 
of this can be seen in the Fgfr2 knockouts, as the receptor protein has multiple functionalities (Molotkov et al., 
2017, Yu et al., 2003). A common strategy to generate an Fgfr2 knockout is through the removal of the 
ligand-binding domain (exons 8-9, IgI loop3). However, this mutant does not result in the complete removal 
of the FGFR2, but instead yields a truncated, albeit non functional, receptor. On the other hand, removal of 
exon 5, common to both Fgfr2b and Fgfr2c isoforms, did not lead to the expression of a truncated receptor 
(Yu et al., 2003, Molotkov et al., 2017). In fact, there are slight phenotypic differences too between these 
knockouts, with the latter Fgfr2c knockout appearing less severe (Yu et al., 2003, Molotkov et al., 2017). 
Targeting constructs recombined between intragenic regions also have an effect on gene expression. Here, 
removal of exon 9 encoding Fgfr2c is able to cause a splice switch that results in ectopic Fgfr2b expression 
(Hajihosseini et al., 2001). LoxP sites were inserted into intergenic regions of Fgfr2 exons 8-10, and 
conditional removal through recombination sems to have increased susceptibility to alternative splicing 
alterations (Hajihosseini et al., 2001). The upregulation of Fgfr2b subsequently shifted the phenotype from a 
Crouzon spectrum to that of Apert (Hajihosseini et al., 2001). Nonetheless, the successful targeting of specific 
genes has been vital to determine gene function contributing towards human disease. 
The advancement of CRISPR-CAS9 will increase efficiency of generating novel mouse models for human 
disease (Singh et al., 2015). Conventional techniques generating mouse models with recombination 
technology has been slow and expensive, and the use of genome editing technologies could overcome these 
issues. This could be particular useful in phenotypic screens for mouse embryos (Adams et al., 2013). There is 
an international effort to delineate the phenotypes of knockout mice generated from the International 
Knockout Mouse Consortium (IKMC). The International Mouse Phenotyping Consortium (IMPC) 
(http://www.mousephenotype.org/), as it became known, aims to phenotypically screen 20,000 knockouts in 
10 years (Adams et al., 2013). The importance of screening phenotypes allows the corroboration between 
genotype to phenotype, and especially in the case of embryonic lethal models that helps to pinpoint critical 
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pathways for development. There are several methods for analysis, with emphasis on 3D imaging such as 
μCT, Optical Projection Tomography (OPT) and High Resolution Episcopic Microscopy (HREM). The 
ultimate aim is to utilise these tools to generate data widely available to researchers. A simlar platform is also 
available specifically aimed for craniofacial development called ‘FaceBase’ (http://www.facebase.org), which 
has a wide range of curated datasets available online, both phenotypic and omics, for craniofacial research 
across multiple organisms. Several groups have contributed to this consortium by generating transcriptomic 
atlases of calvarial sutures, acquired using laser captured microdissection on several mouse models of 
craniosynostosis including Apert and Saethre-Choetzen. Despite the plethora of mouse models generated for 
craniofacial syndromes, few studies have characterised the downstream signalling misregulation that must 
contribute to the phenotype. Further disruption of downstream effectors will undoubtedly help to delineate the 
complex relationship between signal transduction and gene expression. This could be achieved by generating 
mouse models specifically targeting those signalling intermediates. A comprehensive review of these mouse 
models have been listed in a recent review by Dinsmore and Soriano (Dinsmore and Soriano, 2018). As 
growth factor signalling, such as FGF, is critical for craniofacial development, it would also be ideal to adopt 
mouse models that are designed to study cancer progression into birth defects research. This is because mouse 
models such as BrafV6ooE/+ or the KrasG12D/+, have mutations that specifically disrupt multiple levels of a 
signalling cascade (i.e. MAPK/ERK) (Tuveson et al., 2004, Mercer et al., 2005). Future studies will need to 
address the impact of the mutation on cascade activation at the level of the receptor in vivo. For example, it 
has been demonstrated by Miraoui et al., 2009 that the Apert mutation (FGFR2-p.S252W) preferentially 
activates the PLC-PKC cascade for osteogenesis in vitro (Miraoui et al., 2009). There have been attempts in 
the past to elucidate this by mutating binding domains on the catalytic domains of PDGFRs in the mouse 
(Klinghoffer et al., 2002, Klinghoffer et al., 2001, Fantauzzo and Soriano, 2016). As generating a mouse 
mutant for individual binding domain is time consuming, technologies such as CRISPR-CAS9 will no doubt 
assist with this endeavour.     
In conclusion, mouse models offer a robust platform to study craniofacial birth defects. This is in particular to 
clinical syndromes, where a majority of knock in mice carrying a human mutation recapitulate the human 
disease phenotype. Together with conditional mouse models, significant progress has been made to dissect the 
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molecular basis for delineating craniofacial birth defects. With the dawn of genome editing technologies, there 
are exciting opportunities over the horizon, and it is doubtless that mouse models will continue to play a 
central part in biomedical science.   
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Table 1 Overview of mouse models that display features of a syndromic craniosynostosis phenotype. 
 
Gene Mutation/Transgene allele Human syndrome (OMIM#) Affected sutures Mechanism Reference 
Fgf9 N143T SYNS3 (612961) coronal LOF Harada et al 2009 
Fgf3 
mutagenesis Crouzon (123500) coronal overexpression Carlton et al 1998 
Fgf4 
Fgfr1 P250R Pfeiffer (101600) coronal,  interfrontal, sagittal  GOF Zhou et al 2000 
Fgfr2 C342Y Crouzon (123500) 
coronal 
GOF 
Eswarakumar et al 2004  
  W290R Crouzon (123500)   
  S252W 
Apert (101200) coronal, sagittal, lambdoid 
Wang et al 2005 
  S250W Chen et al 2003 
  Y394C Beare-Stevenson (123790) coronal Wang et al 2012 
Fgfr2c Fgfr2c-/- 
N/A 
coronal LOF 
Eswarakumar et al 2002 
  Fgfr2c flox, Fgfr2cflox/- Hajihosseini et al 2001 
Fgfr2b Fgfr2b-/- squamous temporal-parietal LOF De Moerlooze et al 2000 
Fgfr3 P244R Muenke (602849) coronal GOF Twigg et al 2009 
Twist1  Twist1+/- 
Saethre-Chotzen (101400) coronal, sagittal, lambdoid LOF 
Chen 1995, Behr 2011  
Tcf12 Tcf12flox/-; Twist1+/-; EIIaCRE/+ Sharma et al 2013 
Id1 Id1+/-; Twist1+/- 
Connerney et al 2008  
Id3 Id1+/-; Twist1+/- 
Msx2 
  
  
Timp1-P7H 
Boston-type craniosynostosis 
(604757) 
coronal, sagittal, lambdoid 
GOF 
Lin et al 1995 CMV-P7H 
CMV-WT overexpression 
Jag1 
  
 Jag1+/- 
Alagille (118450) 
no phenotype 
LOF Yen et al 2010 
Jag1flox/-; Twist1+/-; Mesp1CRE/+ coronal, sagittal, lambdoid 
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Gli3 Gli3Xt-J/Xt-J 
Carpenter (201000) 
lambdoid 
LOF 
Hui 1993, Rice 2010 
Rab23 Rab23-/- embryonic lethal Eggenschwiler et al 2001 
Megf8 C193R 
sutures not analysed 
Aune et al 2008 
Masp1 
Masp1/3+/- (double KO) 3MC (257920) Takahashi et al 2008 
Masp3 
Hdac4 Hdac4-/- 
Brachydactyly mental 
retardation (600430) 
Vega et al  2004 
Tgfbr1 M318R 
Loeys-Dietz (613795) 
coronal 
GOF Gallo et al 2014 
Tgfbr2 G357W no suture phenotype 
Nell1 WT (CMV) 
N/A 
coronal, sagittal, posterior frontal overexpression Zhang et al 2002 
Axin2 Axin2-/- coronal, interfrontal 
LOF 
  
  
  
Yu et al 1995 
Dusp6 exon 3 STOP, Dusp6+/-  
coronal 
Li et al 2007 
    Dusp6-/- 
Gdf6 Gdf-/- Settle et al 2003 
Pdgfrα D846V (R26R) coronal, interfrontal  overexpression Moenning et al 2009 
  PdgfrαD842V/+; Meox2CRE/+ coronal GOF 
  
He and Soriano 2017 
    PdgfrαD842V/+; Mesp1CRE/+ coronal, lambdoid 
EphA4 EphA4-/- 
coronal 
LOF 
  
Ting et al 2009 
    Twist1+/-; EphA4+/- 
Runx2 Prx1-Runx2 pan-synostosis overexpression Maeno et al 2011 
Erf Erf-/-  
no phenotype LOF 
  
  
Papadaki et al 2007 
  Erf flox, Erfflox/+ Twigg et al 2013 
    Erf flox, Erfflox/- coronal, sagittal, lambdoid 
Frem1 Frameshift (T>C) at intron 25, Frem1bat/+ 
posterior frontal  
hypomorph Smyth et al 2004 
  exon 2 deletion, Frem1QBrick/+ LOF Vissers et al 2011 
LOF = loss of function; GOF = gain of function; N/A = not associated (with a human syndrome) 
